1
Return

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial

delete2026-06-29
delete0
PRE
AI
G
Giulio Francolini *
V
Vanessa Di Cataldo
S
Saverio Caini
P
Pietro Garlatti
M
Michele Aquilano
N
Niccolò Bertini
A
Alessio Bruni
G
Gianluca Ingrosso
R
Rolando M D'Angelillo
L
Luca Tagliaferri
B
Barbara A Jereczek-Fossa
M
Matteo Augugliaro
L
Luca Triggiani
S
Silvana Parisi
L
Lorenzo Masieri
R
Riccardo Campi
R
Richard K Valicenti
G
Gabriele Simontacchi
D
Daniela Greto
P
Pierluigi Bonomo
DOI：10.1016/S1470-2045(26)00178-6delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer. The aim of this analysis is to explore the long-term impact of MDT on overall survival.

Journal

T
The Lancet Oncology
IF:
0
Papers:
348
Citations:
1

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers